• Partner With Us
  • Focus Areas
    • Cause Selection
    • Global Health & Wellbeing
      • Abundance & Growth
      • Effective Giving & Careers
      • Farm Animal Welfare
      • Global Aid Policy
      • Global Health & Development
      • Global Health R&D
      • Global Public Health Policy
      • Scientific Research
    • Global Catastrophic Risks
      • Biosecurity & Pandemic Preparedness
      • Forecasting
      • Global Catastrophic Risks Capacity Building
      • Potential Risks from Advanced AI
    • Other Areas
      • History of Philanthropy
  • Grants
  • Research & Updates
    • Blog Posts
    • In the News
    • Research Reports
    • Notable Lessons
  • About Us
    • Grantmaking Process
    • How to Apply for Funding
    • Careers
    • Team
    • Operating Values
    • Stay Updated
    • Contact Us
  • Partner With Us
  • Focus Areas
    • Cause Selection
    • Global Health & Wellbeing
      • Abundance & Growth
      • Effective Giving & Careers
      • Farm Animal Welfare
      • Global Aid Policy
      • Global Health & Development
      • Global Health R&D
      • Global Public Health Policy
      • Scientific Research
    • Global Catastrophic Risks
      • Biosecurity & Pandemic Preparedness
      • Forecasting
      • Global Catastrophic Risks Capacity Building
      • Potential Risks from Advanced AI
    • Other Areas
      • History of Philanthropy
  • Grants
  • Research & Updates
    • Blog Posts
    • In the News
    • Research Reports
    • Notable Lessons
  • About Us
    • Grantmaking Process
    • How to Apply for Funding
    • Careers
    • Team
    • Operating Values
    • Stay Updated
    • Contact Us

History of Philanthropy Case Study: Clinton Health Access Initiative’s Role in Global Price Drops for Antiretroviral Drugs

  • Focus Area: Global Health & Development
  • Focus Area: History of Philanthropy
  • Portfolio Area: Other Global Health & Development
  • Content Type: Blog Posts
Published: January 10, 2018 | by Holden Karnofsky

A little over a year ago, the HistPhil blog put up a post by Tamara Mann Tweel about a now-published report we commissioned her to work on, regarding the Clinton Health Access Initiative (CHAI)’s role in global price drops for antiretroviral drugs (which can be crucial in treating HIV/AIDS).

The HistPhil post states:

Antiretroviral drugs (ARVs) went down from 10,000 – $15,000 per person per year to $140 per person per year between 2000 and 2005. This price drop inspired governments and international bodies to purchase ARVs and administer therapy to millions of individuals stricken with HIV/AIDS.

 

While the Clinton Foundation often receives credit for the entirety of the ARV price drop, my report affirmed scholarship that claimed the price drop actually occurred in three stages. The first, from $15,000 per person per year to approximately $1000 per person per year in specific cases, can be attributed to activists persuading pharmaceutical companies to offer philanthropic prices to discreet pilot projects; the second price drop, from approximately $1000 per person per year to approximately $350 per person per year, can be attributed to the active creation of an international generic drug market; and the final drop, from $350 to $140, can be attributed to deliberate market interventions into the generic market by the Clinton Health Access Initiative (CHAI).

As discussed in the full report, this three-stage price drop corresponded to a massive increase in the purchases of antivirals (especially by governments and nonprofits); we haven’t specifically estimated the deaths averted by this development, but feel confident that it qualifies as the sort of hit we’re interested in.

We don’t feel fully confident that any particular funder or nonprofit was crucial to the price drop. The key things we learned from the report were that:

  • In the first stage, activists targeted a lawsuit by pharmaceutical companies against South Africa (initially with the support of the U.S. government).
    • The South African Parliament had given its Ministry of Health authority for compulsory licensing and parallel imports of antiretrovirals, and the pharmaceutical companies were suing it for breach of international intellectual property protections.
    • The report states: “Oxfam, ACT UP, and MSF issued press releases and took out ads critical of the pharmaceutical industry. MSF started an online petition demanding that the drug companies drop the lawsuit. ACT UP organized demonstrations in New York City against the pharmaceutical companies outside their corporate offices, featuring slogans like ‘Stop Medical Apartheid of AIDS’ and ‘Drug Company Greed Kills.’ The access NGOs’ ‘name and shame’ campaign was widely considered a success, and the lawsuit became a ‘public relations nightmare’ for the pharmaceutical companies [source].”
    • The US government reversed its position on the lawsuit (though the report cites Fisher and Rigamonti 2005, pg 35-38 for evidence that this wasn’t necessarily purely a function of the activism). Pharma companies dropped the lawsuit, took the “unusual step of reimbursing the South African government for its legal expense,” and began selling drugs at steeply discounted prices to nonprofits such as the UN’s Drug Access Initiative.
    • We’d guess it’s more likely than not that the activists played a crucial role in these changes – as well as in a later agreement at Doha that “foreclosed the possibility of WTO sanctions over compulsory licensing” – but the report did not focus heavily on this phase.
  • In the second stage, the report credits Jamie Love for a major role in arranging for generic manufacturers to sell antiretrovirals at much lower prices, and in much greater volumes, than they would have otherwise. He studied the requirements for manufacturing the drugs, “suggested that a $350 annual per patient ARV price might be possible” due to the possibility of far more sales at this price, and helped a major buyer (MSF) coordinate with manufacturers to plan and execute this change.
  • The third phase is where the report focused, and the HistPhil post summarizes the activities and role of CHAI in working toward further price reductions.
    • Working with a similar “lower prices, more volume” goal that Jamie Love had had, CHAI created a “buying club” to pool purchases – and, perhaps crucially, guarantee growing purchases over time – for developing countries, and used the promise of greater and better-known volume to negotiate price drops. It also “helped source cheaper ingredients, and eventually they even paid chemists to develop less expensive manufacturing and synthesizing techniques.”
    • I felt less convinced than the report’s author that CHAI had clearly been crucial to the final stage of price drops, given the extent of price reduction that had already occurred prior to CHAI’s involvement, but would guess that it at least sped up the reduction.

    For more, see the full report, the HistPhil post, and a Vox.com article that drew on the HistPhil post.

Subscribe to our blog
Open Philanthropy
Open Philanthropy
  • We’re Hiring!
  • Press Kit
  • Governance
  • Privacy Policy
  • Stay Updated
Mailing Address
Open Philanthropy
182 Howard Street #225
San Francisco, CA 94105
Email
info@openphilanthropy.org
Media Inquiries
media@openphilanthropy.org
Anonymous Feedback
Feedback Form

© Open Philanthropy 2025 Except where otherwise noted, this work is licensed under a Creative Commons Attribution-Noncommercial 4.0 International License.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT